Dose‐Escalation and Dose‐Expansion Study to Evaluate the Safety and Tolerability of Anti‐CD7 Allogeneic CAR T‐Cells (WU‐CART‐007) in Patients with CD7+ Hematologic Malignancies. Here, CD7 is linked to cancer.